insights_auto
Why is GSK up 2,37%?
Dive Deeperchevron_right
GSK:NYSE
GSK plc
USDÂ 50,63
arrow_upward
+2,37%(+1,17) 1D
USDÂ 50,63
0,00% (0,00)
bedtimeAfter hours
Closed: 20 Okt., 16:00:02 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
USDÂ 49,98
High
USDÂ 51,12
Low
USDÂ 49,77
Mkt. cap
102,38Â mjd
Avg. vol.
4,74Â m
Volume
5,60Â m
Dividend
3,59%
Quarterly dividend
USDÂ 0,45
Ex-dividend date
13 Aug. 2026
P/E ratio
16,13
52-wk high
USDÂ 61,70
52-wk low
USDÂ 42,84
EPS
USDÂ 3,14
Beta
0,25
Shares outstanding
2,16Â mjd
No. of employees
67Â k
Open
USDÂ 49,98
High
USDÂ 51,12
Low
USDÂ 49,77
Mkt. cap
102,38Â mjd
Avg. vol.
4,74Â m
Volume
5,60Â m
Dividend
3,59%
Quarterly dividend
USDÂ 0,45
Ex-dividend date
13 Aug. 2026
P/E ratio
16,13
52-wk high
USDÂ 61,70
52-wk low
USDÂ 42,84
EPS
USDÂ 3,14
Beta
0,25
Shares outstanding
2,16Â mjd
No. of employees
67Â k
News stories
From web sources and news partners
Zacks
·
7 uur gelede
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth
ad-hoc-news.de
·
8 uur gelede
GSK stock: At 17.97 percent below its 52-week high, GSK stock sits
Zacks Investment Research
·
8 uur gelede
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth
ad-hoc-news.de
·
13 uur gelede
Jefferies keeps Buy rating for GSK stock ahead of results
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66,8Â k
Founded27 Des. 2000
Headquarters-
SectorPharmaceutical industry
Websitegsk.com